Methotrexate in ulcerative colitis: A Spanish multicentric study on clinical use and efficacy

Journal of Crohn's and Colitis

Volumn 5, Issue 5, 2011, Pages 397-401

  Mañosa, Míriam ^a,i   García, Valle ^b   Castro, Luisa ^c   García Bosch, Orlando ^d,i   Chaparro, María ^e,i   Acosta, Manuel Barreiro de ^f   Carpio, Daniel ^g   Aguas, Mariam ^h,i  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f Instituto de Salud Carlos III   (Spain)

^g Complexo Hospitalario de Pontevedra ^*  (Spain)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Inflammatory bowel disease; Methotrexate; Ulcerative colitis

Indexed keywords

FOLIC ACID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; STEROID;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; COLON RESECTION; DATA BASE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL; HUMAN; INFECTION; LIVER TOXICITY; MALAISE; MALE; MULTICENTER STUDY; PATIENT REFERRAL; PNEUMONIA; PRIORITY JOURNAL; REMISSION; SPAIN; TREATMENT FAILURE; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; AGED; AGED, 80 AND OVER; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 80053132333     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.03.012     Document Type: Article

References (35)

1. Faubion W.A., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121(2):255-260.
2. Ho G.T., Chiam P., Drummond H., Loane J., Arnott I.D., Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006, 24(2):319-330.
3. Ardizzone S., Maconi G., Russo A., Imbesi V., Colombo E., Bianchi P.G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55(1):47-53.
4. Fernández Bañares F., Bertrán X., Esteve Comas M., Cabré E., Menacho M., Humbert P., et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996, 91:2498-2499.
5. Doménech E., Garcia-Planella E., Bernal I., Rosinach M., Cabré E., Fluvià L., et al. Azathioprine without oral cyclosporin in the long-term maintenance of remission induced by intravenous cyclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2002, 16:2061-2065.
6. Fraser A.G., Orchard T.R., Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002, 50(4):485-489.
7. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353(23):2462-2476.
8. Gonzalez-Lama Y., Fernandez-Blanco I., Lopez-SanRoman A., Taxonera C., Casis B., Tabernero S., et al. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 2008, 55(86-87):1609-1614.
9. Barreiro-de Acosta M., Lorenzo A., Mera J., Dominguez-Muñoz J.E. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohn's Colitis 2009, 3(4):271-276.
10. Gisbert J.P., Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009, 104(3):760-767.
11. Travis S.P.L., Stange E.F., Lémann M., Oresland T., Bemelman W.A., Chowers Y., et al. European evidence-based consensus on the management of ulcerative colitis: current management. JCC J Crohn's Colitis 2008, 2(1):24-62.
12. Mahadevan U., Sandborn W.J. Diagnosis and management of pouchitis. Gastroenterology 2003, 124(6):1636-1650.
13. Feagan B.G., Rochon J., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995, 332(5):292-297.
14. Feagan B.G., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000, 342(22):1627-1632.
15. Lemann M., Zenjari T., Bouhnik Y., Cosnes J., Mesnard B., Rambaud J.C., et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000, 95(7):1730-1734.
16. Dignass A., Van Assche G., Lindsay J.O., Lemann M., Södelholm J., Colombel J.F., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease:current management. Journal of Crohn's and Colitis 2010, 4:28-62.
17. Kozarek R.A., Patterson D.J., Gelfand M.D., Botoman V.A., Ball T.J., Wilske K.R. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989, 110(5):353-356.
18. Oren R., Arber N., Odes S., Moshkowitz M., Keter D., Pomeranz I., et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996, 110(5):1416-1421.
19. Mate-Jimenez J., Hermida C., Cantero-Perona J., Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000, 12(11):1227-1233.
20. Cummings J.R., Herrlinger K.R., Travis S.P., Gorard D.A., McIntyre A.S., Jewell D.P. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005, 21(4):385-389.
21. Wahed M., Louis-Auguste J.R., Baxter L.M., Limdi J.K., McCartney S.A., Lindsay J.O., et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine. Aliment Pharmacol Ther 2009, 30(6):614-620.
22. Paoluzi O.A., Pica R., Marcheggiano A., Crispino P., Iacopini F., Iannoni C., et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002, 16(10):1751-1759.
23. Kozarek R.A. Methotrexate and ulcerative colitis: Wrong drug?, wrong dose?, or wrong disease?. Gastroenterology 1996, 110:1652-1656.
24. Egan L.J., Sandborn W.J., Tremaine W.J., Leighton J.A., Mays D.C., Pike M.G., et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 1999, 13(12):1597-1604.
25. Braun J., Kastner P., Flaxenberg P., Wahrisch J., Hanke P., Demary W., et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008, 58(1):73-81.
26. Moshkowitz M., Oren R., Tishler M., Konikoff F.M., Graff E., Brill S., et al. The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1997, 11(3):569-573.
27. Oren R., Moshkowitz M., Odes S., Becker S., Keter D., Pomeranz I., et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997, 92(12):2203-2209.
28. Arora S., Katkov W., Cooley J., Kemp J.A., Johnston D.E., Schapiro R.H., et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999, 46(27):1724-1729.
29. Fraser A.G., Morton D., McGovern D., Travis S., Jewell D.P. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16(4):693-697.
30. Schroder O., Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 2003, 98(3):530-537.
31. Present D.H., Meltzer S.J., Krumholz M.P., Wolke A., Korelitz B.I. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989, 111(8):641-649.
32. Connell W.R., Kamm M.A., Dickson M., Balkwill A.M., Ritchie J.K., Lennard-Jones J.E. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994, 343(8908):1249-1252.
33. Korelitz B.I., Fuller S.R., Warman J.I., Goldberg M.D. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 1999, 94(2):424-426.
34. Korelitz B.I., Mirsky F.J., Fleisher M.R., Warman J.I., Wisch N., Gleim G.W. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999, 94(11):3248-3253.
35. Ortiz Z, Shea B, Suarez AM, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2):CD000951.